Introduction
============

Gastric cancer is one of the deadliest malignancies worldwide and remains the second most common cancer and the second leading cause of cancer-related death in China [@B1], [@B2]. Surgery is the only curative approach for resectable cases, either alone or in combination with adjuvant treatment [@B3]. However, most patients present with advanced disease at initial diagnosis, thus missing the chance to undergo radical resection. In addition, the rates of recurrence and distant metastasis in subjects undergoing radical gastrectomy remain high [@B3]. Moreover, although great advances have been made in the early screening, diagnosis and treatment of gastric cancer, the prognosis remains poor, with an estimated 5-year overall survival (OS) rate of less than 40% [@B2], [@B3].

Various tumor related-factors, including tumor size, degree of differentiation, depth of invasion, lymph node status and distant metastasis, along with patient-related factors such as age, sex, and comorbidity have been identified as important prognostic indicators for gastric cancer patients [@B4]. In addition, some inflammation-based prognostic variables such as the platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) have also been established as predictors of long-term survival in such cases [@B5]-[@B7]. However, more accurate and promising biological markers are still needed to classify the risk of unfavorable prognosis and to design optimal therapeutic strategies for patients with gastric cancer.

Fibrinogen, a glycoprotein produced by hepatic cells, is a key regulator of the hemostatic system and plays important roles in blood coagulation, cell-cell adhesion and the systemic inflammatory response [@B8]. In addition, elevated fibrinogen levels have been observed in various malignancies, including gastric cancer, and could promote tumor progression, invasion and distant metastasis [@B9]. Moreover, hyperfibrinogenemia has also been confirmed to be significantly correlated with increased tumor size, advanced tumor stage, and poor prognosis in gastric cancer patients [@B10]-[@B14]. Furthermore, decreased pre-albumin levels are also frequently observed in gastric cancer patients and are correlated with unfavorable survival [@B15]. Most recently, Zhang and his colleagues suggested that the preoperative fibrinogen/pre-albumin ratio (FPR) might be a novel prognostic indicator in patients with surgical stage II and III gastric cancer and that it could precisely distinguish stage III patients who would benefit from adjuvant chemotherapy [@B16].

Therefore, we proposed that a cumulative score based on preoperative fibrinogen in combination with pre-albumin (FP score) might provide more accuracy in predicting long-term survival for resectable gastric cancer patients. The purpose of this study was to examine the correlation of the preoperative FP score with clinicopathologic variables, and to investigate its prognostic significance in resectable gastric cancer patients.

Methods
=======

Patients
--------

The electronic medical records of 396 patients with newly diagnosed gastric cancer from April 2007 to August 2016 in the First Affiliated Hospital of Anhui Medical University in Hefei, China were retrospectively reviewed. Only patients who underwent radical gastrectomy and had histopathologically confirmed gastric cancer were enrolled in the present study. Patients who were diagnosed with other malignancies, underwent neoadjuvant chemotherapy and/or radiotherapy, or had diseases needing anticoagulants that would affect the hemostatic system were excluded. In addition, we excluded subjects without preoperative information on nutrition and hemostasis and patients who died of causes other than gastric cancer. Furthermore, those diagnosed with chronic inflammatory diseases, malnutrition or infections were also excluded. Therefore, a total of 306 cases were enrolled in the final analysis.

Treatment and follow-up
-----------------------

All included patients underwent radical gastrectomy. The median number of dissected lymph nodes was 17 (range, 2 to 68). A total of 243 patients with high rate of local recurrence and/or distant metastasis received adjuvant chemotherapy. Fluorouracil-based two-drug combination chemotherapy was delivered to four-fifths of the patients, whereas the remaining subjects underwent fluorouracil monotherapy. Regular blood tests, including the detection of tumor markers, ultrasound/computed tomography and upper gastrointestinal endoscopy were regularly evaluated after surgery. The patients were followed up via the telephone. The time from resection to recurrence and metastasis recorded by imaging (CT, B-mode ultrasound, MRI, etc.) or histopathological cytology or the time from resection to the last date of follow-up was defined as the DFS. OS was calculated from the date of resection to death from cancer or the most recent follow-up.

Clinical and laboratory variables
---------------------------------

The patients\' baseline characteristics, preoperative fibrinogen and pre-albumin levels, and other parameters, were retrieved and collected from the electronic medical records. Tumor stages were classified according to the AJCC/UICC TNM staging system (the 7th edition). The long diameter measured on the general post-operative pathological specimen was considered the tumor size. The tumor locations were divided into upper, middle, lower and diffuse stomach. The degree of differentiation was categorized into poorly/not differentiated and moderately/well differentiated. The preoperative fibrinogen and pre-albumin concentrations were determined in samples collected within one week before surgery. Plasma fibrinogen levels were tested by an automatic coagulation analyzer (CS-5100, Sysmex, Japan). Serum pre-albumin levels were examined using an automatic biochemical analyzer (Cobas 8000, Roche, Switzerland).

Fibrinogen and pre-albumin score (FP score)
-------------------------------------------

The optimal cut-off value for preoperative fibrinogen was defined as 4.0 g/L according to previous studies and the cut-off value for pre-albumin was determined as 230.0 mg/L with the method available in the X-tile 3.6.1 software [@B17], [@B18] (Yale University, New Haven, CT, USA). Patients with elevated fibrinogen (≥ 4.0 g/L) and decreased pre-albumin (\< 230.0 mg/L) levels were allocated an FP score of 2, those with only one of these two abnormalities were assigned a score of 1, and those with neither of the two abnormalities were allocated a score of 0.

Statistical analysis
--------------------

A chi-square test was used to examine the differences between groups. Survival curves were calculated by the Kaplan-Meier method, and differences were compared with the log-rank test. Cox proportional hazards regression models were utilized to perform univariate and multivariate analyses, and hazard ratios (HRs) for parameters related to DFS and OS were calculated. HRs with 95% confidence intervals (CIs) and two-sided *P* values were reported. All statistical analyses were performed with SPSS 22.0 (SPSS Inc., Chicago, IL, USA). A two-sided *P* \< 0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

The baseline characteristics are summarized in Table [1](#T1){ref-type="table"}. The median age at diagnosis was 60.0 years (range, 21.0-86.0 years). Nearly two-thirds (69.3%) of the patients were males. Most of them (84.0%) presented with T3/T4 disease. Lymph node metastasis was positive in 244 (79.7%) of the patients. Of these, 26 (8.5%) had stage I, 60 (19.6%) had stage II and 220 (71.9%) had stage III. Four-fifths (243, 79.4%) of the cases received adjuvant chemotherapy (Table [1](#T1){ref-type="table"}).

Correlation of preoperative FP score with clinicopathologic variables
---------------------------------------------------------------------

Of the 306 enrolled patients, 113 (36.9%) were assigned an FP score of 0, 133 (43.5%) had an FP score of 1, and 60 (19.6%) had a score of 2 (Table [1](#T1){ref-type="table"}). The analysis demonstrated that the preoperative FP score was significantly correlated with age, tumor size, fibrinogen level, pre-albumin level and white blood cell count. However, no significant differences based on sex, tumor location, degree of differentiation, depth of invasion, lymph node status, tumor-node-metastasis (TNM) stage or adjuvant chemotherapy were identified among the groups (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

Prognostic significance of preoperative FP score in resectable gastric cancer
-----------------------------------------------------------------------------

A survival analysis was then performed to evaluate the prognostic value of the preoperative FP score. A Cox univariate model for DFS revealed that a high preoperative FP score was significantly associated with impaired DFS (HR, 1.482; 95%CI, 1.222-1.796; *P* \< 0.001; Figure [2](#F2){ref-type="fig"}A). Tumor size (\<5/≥5 cm), depth of invasion (T1-2/T3-4), lymph node involvement (negative/positive), TNM stage (I-II/III), adjuvant chemotherapy (yes/no), fibrinogen level (\<4.0/≥4.0 g/L) and pre-albumin level (\<230.0/≥230.0 mg/L) were other significant prognostic parameters identified by univariate analysis (*P* \< 0.05). In the multivariate analysis, the preoperative FP score (HR, 1.434; 95% CI, 1.177-1.747; *P* \< 0.001) remained an independent prognostic indicator for DFS. TNM stage (HR, 2.464; 95% CI, 1.810-3.356; *P* \< 0.001) and adjuvant chemotherapy (HR, 0.213; 95% CI, 0.154-0.294; *P* \< 0.001) were other independent prognostic factors (Table [2](#T2){ref-type="table"}).

Univariate analysis of OS indicated that patients with high preoperative FP scores tended to have unfavorable OS (HR, 1.623; 95% CI, 1.315-2.002; *P* \< 0.001; Figure [2](#F2){ref-type="fig"}B). In addition, other parameters, including age (\<60/≥60 years), tumor size, depth of invasion, lymph node involvement, TNM stage, adjuvant chemotherapy, and fibrinogen and pre-albumin levels, could also significantly predict OS. Multivariate analysis was then performed with a Cox proportional hazards model. After adjusting for other confounding variables, we found that a high preoperative FP score could also serve as an independent predictor for OS (HR, 1.413; 95% CI, 1.136-1.758; *P* = 0.002). As expected, TNM stage (HR, 2.812; 95% CI, 1.941-4.075; *P* \< 0.001) and adjuvant chemotherapy (HR, 0.382; 95% CI, 0.272-0.538; *P* \< 0.001) were two additional significant predictors of OS (Table [3](#T3){ref-type="table"}).

Furthermore, subgroup analysis indicated that a high preoperative FP score was significantly correlated with unfavorable DFS (Figure [3](#F3){ref-type="fig"}C, 4C; *P* \< 0.05) and OS (Figure [3](#F3){ref-type="fig"}D, 4D; *P* \< 0.05) in patients with T3-4 and lymph node positive disease but not DFS or OS in those with T1-2 (Figure [3](#F3){ref-type="fig"}A-B; *P* \> 0.05) or lymph node negative disease (Figure [4](#F4){ref-type="fig"}A-B; *P* \> 0.05).

Discussion
==========

To the best of our knowledge, this study was the first to investigate the prognostic significance of the preoperative FP score in resectable gastric cancer patients. The results showed that the preoperative FP score was significantly correlated with systematic inflammation and the clinical outcome, indicating that those with high preoperative FP scores had a relatively higher risk of local recurrence or distant metastasis, as well as worse prognosis. Therefore, intensive neoadjuvant or adjuvant treatment is strongly suggested for such patients. In addition, subgroup analysis revealed that a high preoperative FP score could significantly predict unfavorable survival in cases with more advanced disease.

It has been recognized that the systemic inflammation response and nutrition status are significantly correlated with tumor progression and prognosis in various malignancies, including gastric cancer [@B19]-[@B22]. Researchers have found that anti-inflammatorg treatment and perioperative nutritional support could reduce the susceptibility to gastric cancer, prevent disease progression and improve the clinical outcome [@B22], [@B23]. In addition, as two crucial inflammatory and nutritional markers, elevated plasma fibrinogen and decreased serum pre-albumin levels have been frequently observed in gastric cancer patients and are associated with poor survival [@B10]-[@B15]. Suzuki T and his colleagues demonstrated that hyperfibrinogenemia was significantly associated with tumor progression and was an independent indicator of poor prognosis (HR, 2.607; 95 % CI, 1.180-5.761; *P* = 0.018) in patients with gastric cancer [@B14]. In addition, Yu X, et al. found that preoperative serum fibrinogen levels were positively correlated with advanced tumor stages and poor survival in gastric cancer subjects undergoing gastrectomy; these markers could also serve as independent risk factors (HR, 1.36; 95 % CI, 1.14-1.62; *P* \< 0.001) for survival in these patients [@B13]. Furthermore, rather than serving as a marker of malnutrition, a decreased pre-albumin level has been identified as an inflammatory indicator and is considered a novel and feasible predictor of unfavorable OS in gastric cancer patients [@B15]. Recently, Han WX, et al. suggested that the preoperative pre-albumin level was closely associated with the hemoglobin level, degree of differentiation and TNM stage. Moreover, it was an independent prognostic indicator (HR, 0.512; 95 % CI, 0.282-0.927; *P* = 0.027), and a low level of pre-albumin was correlated with poor survival in patients with adenocarcinoma of the esophagogastric junction (AEG) who underwent gastrectomy [@B15]. Therefore, it was hypothesized that in combination with fibrinogen, pre-albumin might provide more accuracy in predicting long-term survival in gastric cancer patients.

Most recently, Zhang J and his colleagues investigated the prognostic significance of the preoperative fibrinogen/pre-albumin ratio (FPR) in gastric cancer patients undergoing surgery [@B16]. They found that an elevated preoperative FPR was significantly associated with more advanced tumor invasion, lymph node metastasis and larger tumor size, and it was superior to the levles of fibrinogen, albumin and pre-albumin with regard to independently predicting poor survival in such cases. Moreover, among stage III patients, those with a low FPR appeared to more clearly benefit from adjuvant chemotherapy in comparison with those with a high FPR [@B16]. Consistent with their study, we demonstrated in the present study that the preoperative FP score was significantly correlated with age, tumor size, fibrinogen level, pre-albumin level and white blood cell count, and a high preoperative FP score could significantly predict unfavorable DFS and OS. Moreover, it remained an independent predictor of impaired DFS and OS in the multivariate Cox regression analysis. To the best of our knowledge, this study was the first to report the prognostic value of the preoperative FP score, which was established based on the preoperative fibrinogen and pre-albumin levels in resectable gastric cancer patients.

Although the main limitations of this study were the lack of measurement of other inflammation parameters, the retrospective single-center design and the small sample size, the results showed that the preoperative FP score might serve as a novel and promising marker to predict long-term survival, help more accurately classify patients according to their levels of risk and design optimal therapeutic strategies for resectable gastric cancer patients. However, further studies with large cohorts are warranted to validate these findings.
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###### 

Patient baseline characteristics and their correlations with the preoperative FP score (N = 306)

  Clinicopathologic                    Patients             FP score (N, %)       *P*                                       
  ------------------------------------ -------------------- --------------------- -------------------- -------------------- --------------
  **Age (years)**                                                                                                           \< 0.001^\*^
  \< 60                                143 (46.7)           56 (49.6)             72 (54.1)            15 (25.0)            
  ≥ 60                                 163 (53.3)           57 (50.4)             61 (45.9)            45 (75.0)            
  **Gender**                                                                                                                0.314
  Male                                 212 (69.3)           84 (74.3)             87 (65.4)            41 (68.3)            
  Female                               94 (30.7)            29 (25.7)             46 (34.6)            19 (31.7)            
  **Tumor location**                                                                                                        0.973
  Upper                                123 (40.2)           43 (38.1)             55 (41.4)            25 (41.7)            
  Middle                               60 (19.6)            24 (21.2)             23 (17.3)            13 (21.7)            
  Lower                                72 (23.5)            27 (23.9)             33 (24.8)            12 (20.0)            
  Diffuse                              51 (16.7)            19 (16.8)             22 (16.5)            10 (16.6)            
  **Tumor size (cm)**                                                                                                       \< 0.001^\*^
  \< 5                                 131 (42.8)           60 (53.1)             53 (39.8)            18 (30.0)            
  ≥ 5                                  175 (57.2)           53 (46.9)             80 (60.2)            42 (70.0)            
  **Differentiation**                                                                                                       0.694
  Well/Moderate                        71 (23.2)            29 (25.7)             28 (21.1)            14 (23.3)            
  Poor/Undifferentiated                235 (76.8)           84 (74.3)             105 (78.9)           46 (76.7)            
  **T stage**                                                                                                               0.193
  T1/T2                                49 (16.0)            23 (20.4)             20 (15.0)            6 (10.0)             
  T3/T4                                257 (84.0)           90 (79.6)             113 (85.0)           54 (90.0)            
  **Lymph node status**                                                                                                     0.810
  Negative                             62 (20.3)            25 (22.1)             26 (19.5)            11 (18.3)            
  Positive                             244 (79.7)           88 (77.9)             107 (80.5)           49 (81.7)            
  **TNM stage**                                                                                                             0.404
  I                                    26 (8.5)             14 (12.4)             9 (6.8)              3 (5.0)              
  II                                   60 (19.6)            23 (20.4)             26 (19.5)            11 (18.3)            
  III                                  220 (71.9)           76 (67.2)             98 (73.7)            46 (76.7)            
  **Adjuvant chemotherapy**                                                                                                 
  No                                   63 (20.6)            17 (15.0)             28 (21.1)            18 (30.0)            0.067
  Yes                                  243 (79.4)           96 (85.0)             105 (78.9)           42 (70.0)            
  **Preoperative fibrinogen level**                                                                                         \< 0.001^\*^
  \[g/L; median (range)\]              3.36 (1.19-7.15)     3.00 (1.19-3.97)      3.26 (1.33-5.18)     4.53 (4.01-7.15)     
  **Preoperative pre-albumin level**                                                                                        \< 0.001^\*^
  \[g/L; median (range)\]              224.5 (77.0-409.0)   268.0 (231.0-409.0)   203.0 (86.0-342.0)   180.0 (77.0-225.0)   
  **Preoperative WBC count**                                                                                                \< 0.001^\*^
  \[(k/cm^3^); median (range)\]        5.39 (2.47-14.16)    5.24 (2.70-14.16)     5.07 (2.47-10.63)    6.94 (3.51-14.15)    

FP, fibrinogen and pre-albumin; TNM, tumor-node-metastasis; WBC, white blood cell. ^\*^*P* \< 0.05.

###### 

Clinicopathological factors, FP score, and DFS: univariate and multivariate analyses (N = 306)

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                   Univariate analysis   Multivariate analysis                                        
  ------------------------------------------- --------------------- ----------------------- -------------- ------- ------------- --------------
  Age (\< 60 vs. ≥ 60 years)                  1.216                 0.911-1.263             0.183                                NI

  Gender (Male vs. Female)                    1.008                 0.740-1.373             0.959                                NI

  Tumor location\                             1.027                 0.902-1.168             0.689                                NI
  (Upper/Middle vs. Lower/Diffuse)                                                                                               

  Tumor size (\< 5 vs. ≥ 5 cm)                1.611                 1.191-2.178             0.002^\*^      1.258   0.920-1.720   0.151

  Differentiation\                            1.139                 0.803-1.615             0.466                                NI
  (Well/Moderate vs. Poor/Undifferentiated)                                                                                      

  Depth of invasion (T1/T2 vs. T3/T4)         1.820                 1.155-2.868             0.010^\*^                            NI

  Lymph node involvement\                     3.073                 1.930-4.893             \< 0.001^\*^                         NI
  (Negative vs. Positive)                                                                                                        

  TNM stage (I vs. II/III)                    2.189                 1.613-2.970             \< 0.001^\*^   2.464   1.810-3.356   \< 0.001^\*^

  Adjuvant chemotherapy (No vs. Yes)          0.290                 0.211-0.397             \< 0.001^\*^   0.213   0.154-0.294   \< 0.001^\*^

  Pre-albumin (\< 230 vs. ≥ 230 g/L)          1.639                 1.221-2.200             0.001^\*^                            NI

  Fibrinogen (\< 4 vs. ≥ 4 g/L)               1.559                 1.149-2.115             0.004^\*^                            NI

  FP score (0 vs. 1/2)                        1.482                 1.222-1.796             \< 0.001^\*^   1.434   1.177-1.747   \< 0.001^\*^
  ---------------------------------------------------------------------------------------------------------------------------------------------

DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; NI, not included. ^\*^*P* \< 0.05.

###### 

Clinicopathological factors, FP score, and OS: univariate and multivariate analyses (N = 306)

  Variables                                                  Univariate analysis   Multivariate analysis                                        
  ---------------------------------------------------------- --------------------- ----------------------- -------------- ------- ------------- --------------
  Age (\< 60 vs. ≥ 60 years)                                 1.474                 1.078-2.016             0.015^\*^      1.383   1.002-1.909   0.049^\*^
  Gender (Male vs. Female)                                   0.898                 0.643-1.255             0.529                                NI
  Tumor location (Upper/Middle vs. Lower/Diffuse)            1.002                 0.873-1.151             0.975                                NI
  Tumor size (\< 5 vs. ≥ 5 cm)                               1.728                 1.244-2.399             0.001^\*^      1.212   0.862-1.704   0.269
  Differentiation (Well/Moderate vs.Poor/Undifferentiated)   1.323                 0.903-1.940             0.151                                NI
  Depth of invasion (T1/T2 vs. T3/T4)                        2.365                 1.390-4.062             0.002^\*^                            NI
  Lymph node involvement (Negative vs. Positive)             3.616                 2.123-6.159             \< 0.001^\*^                         NI
  TNM stage (I vs. II/III)                                   2.758                 1.919-3.965             \< 0.001^\*^   2.812   1.941-4.075   \< 0.001^\*^
  Adjuvant chemotherapy (No vs. Yes)                         0.415                 0.296-0.580             \< 0.001^\*^   0.382   0.272-0.538   \< 0.001^\*^
  Pre-albumin (\< 230 vs. ≥ 230 g/L)                         1.853                 1.345-2.554             \< 0.001^\*^                         NI
  Fibrinogen (\< 4 vs. ≥ 4 g/L)                              1.670                 1.205-2.315             0.002^\*^                            NI
  FP score (0 vs. 1/2)                                       1.623                 1.315-2.002             \< 0.001^\*^   1.413   1.136-1.758   0.002^\*^

OS, overall survival. ^\*^*P* \< 0.05.
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